Dosage and Administration for Intravenous Use of Uptravi

Uptravi is a medicine that helps people with pulmonary arterial hypertension (PAH). It’s usually taken as a tablet, but it can also be given through an IV if someone needs to stop taking the tablets for a while.

To switch from oral tablets to IV treatment, doctors need to follow specific guidelines. This ensures that patients get the right dose and don’t miss any treatments.

It’s very important to give Uptravi correctly through an IV.

The medicine must be mixed with water, diluted, and given at the right time to work properly and avoid side effects. Doctors must follow established rules to keep patients safe and manage their condition effectively.

123

Dosage and Administration Guidelines

Uptravi (selexipag) intravenous administration is indicated for patients with pulmonary arterial hypertension (PAH) who are temporarily unable to take oral therapy. The dosage corresponds to the patient’s current oral dose of Uptravi tablets. For example, a patient taking 200 mcg orally twice daily would receive 225 mcg intravenously twice daily.

Concentration and Dilution Requirements:

• Uptravi IV should be diluted with 0.9% sodium chloride or 5% dextrose in water before administration.

• The final concentration should be prepared according to the prescribed dose and infusion volume.

Infusion Rate:

• Administer as a twice-daily intravenous infusion over a period of 80 minutes.

Patient-Specific Factors:

• Adjustments may be necessary based on the patient’s functional class (WHO FC II-III), comorbidities, and tolerability.

• Contraindications include hypersensitivity to selexipag or any excipients in the formulation.

Monitoring Parameters:

• Monitor for infusion-site reactions, as these are more common with IV administration compared to oral.

• Regular assessment of liver function and signs of worsening PAH is recommended.

For detailed prescribing information, refer to the full guidelines .

1www.uptravihcp.com

Administering Uptravi Intravenously

Uptravi, used for pulmonary arterial hypertension (PAH), can be administered intravenously when oral tablets are not feasible.

• The dosage corresponds to the patient’s current oral dose of Uptravi tablets.
• Dilute Uptravi IV with 0.9% sodium chloride or 5% dextrose in water before administration.
• Prepare the final concentration according to the prescribed dose and infusion volume.
• Administer as a twice-daily intravenous infusion over an 80-minute period.
• Adjustments may be necessary based on patient-specific factors, such as functional class (WHO FC II-III), comorbidities, and tolerability.
• Contraindications include hypersensitivity to selexipag or any excipients in the formulation.

Monitor for infusion-site reactions and regularly assess liver function and signs of worsening PAH. For detailed prescribing information, refer to the full guidelines.